Page 176 - CW E-Magazine (5-12-2023)

CPHI Barcelona 2023

Centre’ which showcased the ‘Better manufacturing organisations (CMOs) significant shift from last year’s survey
Stands’ programme, a move towards is likely to be accessible for most bio- when the expectation was that changes
reusable and recyclable exhibition stands, techs in the year ahead, demand could would take up to 5-years. Around 93%
as well as initiatives such as renewable be constrained in the future as more and of executives said that ‘visibility on
electricity, waste reduction and vege- more biologics commercialise. This is supply chain partner’s sustainability
tarian and vegan food options. even as CMO capacity rising from 35% record’ is either ‘extremely important’
of available reactors to 45% by 2027. or ‘important’.
The trade show also featured an
extensive conference agenda covering The report noted that the majority The rate of change is also increas-
a wide range of topics, including next- of cell culture capacity is currently ing and 60% of executives forecast that
gen biomanufacturing, partnering for in-house, and the distribution of this innovators will require CDMOs to imple-
success, formulating the future, future capacity is highly concentrated within ment sustainability metrics as a part
therapies, manufacturing 4.0, patient just ten companies. These account for of contracts with the next two years.
centric development, creating a circular 54% of capacity in 2023 and this will A further 20% anticipate that CDMOs
economy, quality management funda- rise to 57% in 2027 – however, CMOs will be expected to show ESG goals
mentals, and hiring for diversity. like Fujifilm Diosynth and Celltrion, as part of any supplier deals, with just
based on recent substantial capacity 20% believing that only ‘cost and cap-
Biologics capacity predictions investments, will displace two big abilities’ will remain an innovator’s
The demand-supply trends in the pharma companies in the top ten single factor in assigning new contract
biologics sector were highlighted in the (Novartis and Sanofi). decisions.
findings of the CPHI Annual Report
released at the event. Committed to sustainability Only 9% of the pharma companies
Meanwhile, new findings announ- stated they had ‘no current green manu-
The report predicted demand for bio- ced at the CPHI Barcelona, pointed out facturing activities’. The most popular
logics to reach 4,400-KL by 2027 (up that sustainability goals and metrics initiatives currently in use across the
from 2,500KL in 2022) – with a growth are now being implemented across the industry include waste and water reduc-
rate of 11.5% per year and capacity pharma supply chain, with the rate of tion programmes; process improvement
increasing during the same period to adoption accelerating quickly. working groups (including green
8,400-KL (up from 6,550 in 2023). chemistries, metal catalysis, continuous
A majority of CDMOs are expected processing, etc.) and manufacturing
While the capacity at contract to use them within the next 2-years, a equipment optimisation.

CPHI PHARMA AWARD WINNERS 2023
CPHI awards recognise innovation across pharma

supply chain

The 2023 CPHI Pharma Awards, capacity to further increase production. Formulation’ category for the develop-
given away at the CPHI Barcelona, recog- In the ‘API Development’ category, ment and launch of the first solubility-
nised outstanding achievements and Snapdragon Chemistry (a Cambrex enhancing excipient to be specifically
contributions from the global pharma company) was selected as the winner designed for parenteral use in over 20
industry and supply chain across 12 for the development of an ultra-high years.
categories. temperature (>300°C) continuous flow
manufacturing process for racemisation A manufacturing platform, deve-
Mr. Enrico Zodio, CEO of Procos, of Lumakras, sotorasib. This innovative loped by Luminary Therapeutics, that
walked away with the ‘CEO of the approach harnessing greener techno- aims to bring allogeneic cell therapies
Year’ award – for spearheading the logy resulted in a 58% reduction of into the marketplace for under $10,000
company’s impressive development Process Mass Intensity (PMI). was the winner in the ‘Manufacturing
and growth into a leading global Excellence’ category.
CDMO. Procos now turns over in Lubrizol Life Science Health was
excess of €200-mn, having invested in adjudged the winner in the ‘Finished Gasporox took the honours in the

176 Chemical Weekly December 5, 2023

Contents Index to Advertisers Index to Products Advertised